Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy
نویسندگان
چکیده
منابع مشابه
Bone density loss after risk reducing salpingo-oophorectomy
Women undergoing risk-reducing salpingo-oophorectomy through the Prince of Wales Hospital Hereditary Cancer Clinic are offered enrolment in a prospective study of bone mineral density (BMD), markers of bone metabolism and cardio-vascular risk factors. Participants are invited to enroll a friend who has ovaries in situ and are aged within five years of the participant as a control population. Lu...
متن کاملThe impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy.
PURPOSE Preventive health strategies for women at increased hereditary risk of ovarian cancer include gynecologic screening (GS) and/or prophylactic oophorectomy (PBSO). Hormone replacement therapy (HRT) is often prescribed to compensate for postsurgical endocrine deficiencies. This study examined the impact of HRT use on levels of endocrine symptoms and sexual functioning among premenopausal w...
متن کاملRisk-reducing salpingo-oophorectomy for BRCA mutation carriers.
It has been twenty years since the region of the BRCA1mutationwas identified on chromosome 17q. There are now over 3000 risk reducing salpingo-oophorectomy (RRSO) cases reported and an estimated 150 cases describing unsuspected cancers of the ovaries and tubes or in situ lesions. Connor et al. in their current study add to the literature on RRSO outcomes [1]. They report on 345 cases of RRSO in...
متن کاملWhat have we learned from risk-reducing salpingo-oophorectomy?
In this issue of the Journal, Rebbeck et al. (1) have provided us with a meticulously executed, up-to-date meta-analysis that quantifies the reductions in the risks of breast and ovarian/fallopian tube cancer that follow risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 and BRCA2 (BRCA1/2) mutation carriers. Their conclusion — " The summary risk reduction estimates presented here indicate tha...
متن کاملOral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.
Germline mutations in BRCA1 or BRCA2 genes redispose to hereditary breast and ovarian cancers. he estimated lifetime risk of breast cancer in BRCA1 utation carriers ranges from 50% to 80%, while the stimated lifetime risk of ovarian cancer ranges from 0% to 65%. Although breast cancer risk is similar in omen who inherit BRCA2 mutations, the lifetime risk f ovarian cancer is approximately 20% [1...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Acta Obstetricia et Gynecologica Scandinavica
سال: 2017
ISSN: 0001-6349
DOI: 10.1111/aogs.13120